Department of Drug Sciences, University of Catania, Catania, Italy.
Neurosciences, University of Catania, Catania, Italy.
Pharm Dev Technol. 2021 Oct;26(8):824-845. doi: 10.1080/10837450.2021.1950186. Epub 2021 Jul 15.
Scientific research has focused its attention on finding an alternative route to systemic oral and parenteral administration, to overcome their usual drawbacks, such as hepatic first-pass which decreases drug bioavailability after oral administration, off-target effects, low patient compliance and low speed of onset of the pharmacological action in first-aid cases. Innovative drug delivery systems (DDS), mainly based on polymer and lipid biocompatible materials, have given a great prompt in this direction in the last years. The intranasal (IN) route of administration is a valid non-invasive alternative. It is highly suitable for self-administration, the drug quickly reaches the bloodstream, largely avoiding the first pass effect, and can also reach directly the brain bypassing BBB. Association of IN route with DDS can thus become a winning strategy for the controlled delivery of drugs, especially when a very quick effect is desired or needed. This review aims at analyzing the scientific literature regarding IN-DDS and their different ways of administration (systemic, topical, pulmonary, nose-to-brain). In particular, attention was devoted to polymer- and lipid-based micro- and nanocarriers, being the topic of most published articles in the last decade, but the whole plethora of colloidal DDS investigated in recent years for IN administration was presented.
科学研究一直致力于寻找一种替代全身口服和肠胃外给药的途径,以克服它们通常存在的缺点,如口服后药物生物利用度降低的肝脏首过效应、非靶效应、低患者依从性和急救情况下药物药理作用起效慢。在过去几年中,基于聚合物和脂质生物相容性材料的创新药物递送系统(DDS)在这方面取得了很大的进展。鼻腔(IN)给药途径是一种有效的非侵入性替代方法。它非常适合自我给药,药物迅速进入血液,在很大程度上避免了首过效应,并且还可以直接绕过 BBB 到达大脑。因此,将 IN 途径与 DDS 联合使用可能成为药物控制递送的一种成功策略,特别是当需要或期望快速起效时。本综述旨在分析关于 IN-DDS 及其不同给药方式(全身、局部、肺部、鼻内至脑)的科学文献。特别关注基于聚合物和脂质的微载体和纳米载体,这是过去十年中大多数已发表文章的主题,但也介绍了近年来为 IN 给药而研究的整个胶体 DDS 。
Pharm Dev Technol. 2021-10
Curr Med Chem. 2019
Bioorg Med Chem. 2017-11-4
Crit Rev Ther Drug Carrier Syst. 2017
Recent Pat Nanotechnol. 2020
Dev Ophthalmol. 2016
Drug Deliv Transl Res. 2025-1-29
Curr Pharm Des. 2025
Pharmaceuticals (Basel). 2024-6-11